Welcome to our dedicated page for Aprea Therapeutics SEC filings (Ticker: APRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aprea Therapeutics, Inc. (Nasdaq: APRE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer. Aprea files reports with the U.S. Securities and Exchange Commission as a Delaware corporation with common stock listed on The Nasdaq Stock Market LLC under the symbol APRE.
Among the key documents available through EDGAR are Aprea’s Form 8-K current reports, which the company uses to furnish earnings press releases, clinical program updates, financing announcements, and changes to its corporate presentation slide decks. For example, recent 8-K filings reference quarterly financial results, clinical updates from the ACESOT-1051 WEE1 inhibitor trial and the ABOYA-119 ATR inhibitor trial, and the establishment of a recommended Phase 2 dose for ATRN-119. Other 8-Ks describe private placement financing and the extension of projected cash runway.
Investors can also use the filings feed to monitor how Aprea discusses its lead programs, APR-1051 and ATRN-119, in official documents, including descriptions of trial objectives, biomarker-defined patient populations, and risk factor language incorporated by reference in periodic reports. While this page focuses on real-time access to filings such as 8-Ks, users can also locate annual reports on Form 10-K, quarterly reports on Form 10-Q, and any registration statements or prospectus supplements that relate to equity offerings mentioned in company news.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand topics such as clinical milestones, financial condition, and strategic shifts like pausing monotherapy enrollment to consider combination therapies. The platform also surfaces new filings as they are posted to EDGAR, allowing close tracking of Aprea’s regulatory and disclosure history over time.
Aprea Therapeutics president and CEO Gilad Oren reported new equity awards. He received stock options for 80,700 shares of common stock at an exercise price of
Oren was also granted 20,175 restricted stock units that vest in three equal annual installments beginning on
Aprea Therapeutics reported that SrVP/CFO/Principal Financial and Accounting Officer John P. Hamill received new equity compensation. He was granted 40,380 stock options with an exercise price of $0.765 per share, expiring on March 12, 2036.
Twenty-five percent of these options vest on March 12, 2027, with the remainder vesting monthly over the following 36 months, contingent on continued employment. Hamill also received 10,095 restricted stock units, vesting in three equal annual installments starting March 12, 2027. Following the RSU grant, his common stock holdings total 43,528 shares.
Aprea Therapeutics, Inc. reported fourth quarter and full-year 2025 results and provided a corporate update. For 2025, grant revenue was
Total operating expenses for 2025 were
On the balance sheet, total assets at December 31, 2025 were
Aprea Therapeutics registers 12,577,714 shares for resale by private placement investors. This registration covers up to 12,577,714 shares of Common Stock consisting of 1,877,677 shares issued in the January 30, 2026 private placement, 4,411,180 shares issuable upon exercise of pre-funded warrants, and 6,288,857 shares issuable upon exercise of common warrants.
The company is not offering any shares for its own account and will not receive proceeds from resales, although it will receive proceeds from any cash exercise of warrants. The filing discloses an exercise price of
Aprea Therapeutics reported new early clinical signals for its WEE1 inhibitor APR-1051 from the ongoing Phase 1 ACESOT-1051 trial in advanced solid tumors. A second unconfirmed partial response was seen in a patient with advanced endometrial cancer at the 220 mg dose, showing a 50% reduction in target lesions and an 87% drop in CA-125, from 362 U/mL to 47 U/mL. The tumor carries a PPP2R1A mutation, and the patient has only experienced Grade 1 treatment-emergent side effects and remains on therapy. Across the study, 22 patients have been treated at doses from 10 mg to 220 mg, and a further trial update is planned for the second quarter of 2026.
Nantahala Capital Management and its principals report a 4.50% beneficial stake in Aprea Therapeutics, Inc. common stock as of December 31, 2025. They collectively report beneficial ownership of 411,520 shares, including 205,760 shares that can be acquired within sixty days through exercise of warrants.
Nantahala, Wilmot B. Harkey, and Daniel Mack report zero sole voting or dispositive power and shared voting and dispositive power over all 411,520 shares. They state the holdings are owned in the ordinary course of business and are not intended to change or influence control of Aprea Therapeutics.
Aprea Therapeutics’ President and CEO Gilad Oren, who is also a director, reported buying 28,100 shares of common stock in a private placement that closed on January 30, 2026 at $0.89 per share. After this purchase, he directly holds 373,720 common shares, with additional indirect holdings of 1,200 shares by his daughter and 600 shares by his son.
Oren also received 28,100 common warrants with an exercise price of $0.765 per share, immediately exercisable but subject to limits so his ownership generally cannot exceed 4.99% of outstanding common stock or 9.99% of combined voting power. These warrants expire on the second anniversary of the earlier of the effectiveness of a registration statement for the underlying shares or the date those shares become eligible for sale under Rule 144 on a cashless basis.
Aprea Therapeutics’ Senior Vice President and CFO John P. Hamill bought 5,700 shares of common stock in a private placement on January 30, 2026 at
He also received common warrants to purchase up to 5,700 additional shares at an exercise price of
Aprea Therapeutics, Inc. entered into a securities purchase agreement for a private placement of 6,288,857 shares of common stock or pre-funded warrants, together with common stock warrants to purchase up to 6,288,857 shares. The combined effective offering price per share or pre-funded warrant plus accompanying warrant is $0.89, for expected aggregate gross proceeds of approximately $5.6 million.
The common warrants have a $0.765 exercise price, a two-year term starting after resale registration effectiveness or Rule 144 eligibility, and 4.99% or 9.99% ownership caps, with cashless exercise allowed in certain cases. Aprea agreed to file and maintain a resale registration statement and accepted issuance and variable-rate financing restrictions for defined periods. Maxim Group LLC will receive a 7% cash fee on gross proceeds and reimbursement of up to $35,000 in expenses. The company also reported a first unconfirmed partial response in its ongoing Phase 1 ACESOT-1051 study and updated its corporate presentation.